Adjuvant therapy
Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky*, Read More
Association of MammaPrint With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky, VK Read More
70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up study
Title: 70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage Read More
MammaPrint 3-year outcomes with CT with/without anthracycline
ASCO 2024, #511 Presenter: O'Shaughnessy et al.
Read MorePrediction of chemotherapy benefit by MammaPrint®, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 29 Authors: Audeh et al.
Read MoreAPHINITY (BIG 4-11) Trial: BluePrint prediction of CT Benefit w/ HER2-positive
APHINITY Trial (BIG 4-11) Authors: Krop, Piccart, et al
Read MoreRacial Disparities in HR+HER2- ESBC, Reid et al., SABCS 2023 Abstract
SABCS 2023, PO1-28-01 Authors: Sonya Reid et al.
Read MoreRacial Disparities in Latin American Patients-FLEX, Mazo Canola et al., SABCS 2023 Abstract
SABCS 2023, PS18-04 Authors: Marcela Mazo Canola et al.
Read MoreResponse Predictive Subtypes in Lobular Tumors-FLEX, Mukhtar et al., SABCS 2023 Abstract
SABCS 2023, PO4-02-03 Authors: Mukhtar et al.
Read MoreMINDACT & TAILORx Exploratory Comparison, Neven et al., SABCS 2023 Abstract
SABCS 2023, PO1-02-05 Authors: Patrick Neven et al.
Read More
